Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Shares Outstanding

Last Annual Value

33.82M

3-Year CAGR

13%

5-Year CAGR

7%

10-Year CAGR

4%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of shares-outstanding

ANEB · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
33.82M
10.5%7.7%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
9.86M
23.4%26.2%N/A
32.97M
23.9%55.1%N/A
71.87M
3.2%11.0%N/A
92.99M
20.2%37.3%49.3%
52.23M
15.3%17.0%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
8.38M
1.0%0.6%N/A
75.82M
16.8%9.8%N/A
42.42M
1.5%8.3%12.9%
43.26M
5.1%7.8%N/A
766.60K
15.3%4.8%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72